Top of Mind

Weighing the GLP-1 market

Published on19 APR 2024

The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can or wants to take them. Just how large the addressable market for GLP-1s actually is, and what that means for the drug companies developing them, other exposed industries, and the wider economy, is Top of Mind.

Goldman Sachs Research

Weighing the GLP-1 market

Read The Report

Explore More Insights